Exogenous surfactant treatment before and after sixteen hours of ischemia in experimental lung transplantation.
OBJECTIVE
A syngeneic, acute, double lung transplant model in the rat was used to determine the impact of exogenous surfactant treatment on graft function after prolonged cold storage.


METHODS
The donor grafts were flush perfused, preserved for 16 hours, and then reperfused for 120 minutes. Untreated lungs served as controls (group I). In group II the recipient received a 200 mg/kg dose of surfactant (CuroSurf) before reperfusion. In groups III and IV, surfactant was administered before perfusion and harvesting (III, 20 mg/kg; IV, 200 mg/kg). Serial measurements of graft pulmonary vascular resistance, alveolar-arterial oxygen difference, and compliance were obtained. Final graft assessment included weight gain and histologic study.


RESULTS
Repeated-measures analysis of variance showed significant improvement of graft performance in respect to compliance, alveolar-arterial oxygen difference, and pulmonary vascular resistance in donor surfactant treatment group IV (200 mg/kg) in comparison with recipient treatment (group II) and untreated controls (group I). Reducing the donor surfactant supplementation from 200 mg/kg to 20 mg/kg (group III) improved oxygenation and lung compliance as compared with untreated controls. Grafts in groups I and II had significantly more weight gain after 2 hours of reperfusion. Recipient treatment resulted in significantly more pulmonary hemorrhage in histologic sections.


CONCLUSIONS
Donor treatment with exogenous surfactant is advantageous for preservation of graft function after extended ischemia. Positive effects may be seen with as little as 20 mg/kg of exogenous surfactant given before donor organ perfusion.
Hausen
B
B
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
Rohde
R
R
Hewitt
C W
CW
Schroeder
F
F
Beuke
M
M
Ramsamooj
R
R
Schäfers
H J
HJ
Borst
H G
HG
D000403:Airway Resistance; D000818:Animals; D004305:Dose-Response Relationship, Drug; D006085:Graft Survival; D006324:Heart Arrest, Induced; D008168:Lung / Q000473:pathology; D016040:Lung Transplantation; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors
D011663:Pulmonary Surfactants